Patrys : Receives R&D Tax Incentive Refund

ASX announcement

Patrys Receives R&D Tax Incentive Refund

Melbourne, Australia; 8 January, 2019: Patrys Limited (ASX: PAB), a clinical stage biotechnology company, is pleased to announce it has received a $556,129 R&D Tax Incentive Refund for the 2017/2018 financial year.

The Australian Government R&D Tax Incentive encourages companies to engage in R&D benefiting Australia, by providing a tax offset of up to 43.5% (refundable) for eligible R&D activities.

"Patrys is very pleased to further strengthen it's financial position with the receipt of these funds from the Federal R&D Tax Incentive. Following-on from the recently-announced $3 million insurance settlement Patrys now has a secure financial base from which to fund its efforts as it progresses PAT-DX1 towards the clinic," said Dr. James Campbell, Chief Executive Officer and Managing Director of Patrys. "Patrys is anticipating the completion of several pre-clinical studies in the current quarter, and continues to deliver on its development plan that combines long term operation goals with a range of short and medium term value drivers," he said.

-Ends-

For further information, please contact:

Patrys Limited:	Patrys IR:
James Campbell	Ben Walsh
Chief Executive Officer	WE Buchan
P: [phone]	P: [phone]
[e-mail]	[e-mail]
About Patrys Limited:

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of antibodies as therapies for a range of different cancers. Patrys has a pipeline of anti-cancer antibodies for both internal development and as partnering opportunities. More information can be found atwww.patrys.com.

1